KYTRIL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYTRIL (granisetron) is an injectable small-molecule 5-HT3 receptor antagonist approved in 1993 for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea/vomiting (PONV). Administered intravenously, it blocks serotonin signaling in the chemoreceptor trigger zone and GI tract to prevent emesis in cancer patients and surgical populations.
LOE Approaching
Product is in late-stage life cycle with moderate competitive pressure (30/100), signaling smaller brand teams focused on margin protection and managed care negotiations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
Started Apr 2007
171 enrolled
Post-Operative Nausea and Vomiting
Career Relevance
KYTRIL roles are concentrated in market access, managed care, and field operations—not early-stage development or brand building. Career growth on this asset is limited; professionals typically transition to growth-stage products or specialty markets within 2–3 years.
Brand Manager
Worked on KYTRIL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.